Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

2'-Fucosyllactose attenuates estrogen-deficiency-associated bone loss and intestinal dysfunction in ovariectomized rats.

Created on 15 Aug 2026

Authors

Shengpeng Su, Lin Yang, Shusen Li, Zhifei Gou, Erna Sun, Qiruonan Shen, Ziqiang Li, Lin Wang, Yafei He, Jianlong Wang, Wentao Zhang, Chenyuan Wang, Julong Liu

Published in

Journal of the science of food and agriculture. Aug 14, 2026. Epub Aug 14, 2026.

Abstract

Postmenopausal osteoporosis (PMO), driven primarily by estrogen deficiency, is the most prevalent form of osteoporosis and a major global health burden. Estrogen deficiency disrupts gut microbial homeostasis, compromises intestinal barrier integrity and promotes inflammatory bone loss partly through dysregulation of the osteoprotegerin (OPG)/receptor activator of nuclear factor-κB ligand (RANKL) axis. However, the safety concerns and poor adherence associated with long-term pharmacotherapy underscore the need for safer nutritional strategies. Here, we evaluated the protective effects of 2'-fucosyllactose (2'-FL), a natural milk oligosaccharide, against PMO using chondroitin sulfate (CS) as a comparator.
The results showed that 2'-FL restored the balance of the OPG/RANKL axis, improved intestinal integrity and reduced inflammatory cytokine levels. Linear discriminant analysis effect size-based analysis further indicated that 2'-FL may reshape the gut microbiota by promoting the enrichment of selected beneficial microbial taxa, including Adlercreutzia, Gordonibacter and Akkermansia, at the same time as reducing the relative abundance of Ruminococcus and Prevotella under estrogen-deficient conditions. Moreover, 2'-FL exhibited comparable efficacy to CS in restoring bone homeostasis.
Collectively, these findings demonstrate that 2'-FL alleviates both bone loss and intestinal dysfunction under estrogen-deficient conditions. 2'-FL improved bone microarchitecture, favourably modulated bone-remodelling and intestinal barrier-associated markers, reduced inflammation and concurrently altered gut microbial composition. © 2026 Society of Chemical Industry.

PMID:
42601231
Bibliographic data and abstract were imported from PubMed on 15 Aug 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 6
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement